High levels of both sPD-1 and sPD-L1 were associated with a marked decrease in the PBMC immune response to DTaP in patients who recovered from COVID-19 and patients with COVID-19 as compared with healthy controls (Figure 3, I and J). This evidence concerns the gene SPDL1 and COVID-19.